First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

被引：0

作者：

Andre, Thierry

Elez, Elena

Lenz, Heinz-Josef

Jensen, Lars Henrik

Touchefeu, Yann

Van Cutsem, Eric

Garcia-Carbonero, Rocio

Tougeron, David

Mendez, Guillermo

Schenker, Michael

de la Fouchardiere, Christelle

Limon, Maria Luisa

Yoshino, Takayuki

Li, Jin

Aubin, Francine

Cela, Elvis

Chen, Tian

Lei, Ming

Jin, Lixian

Lonardi, Sara

机构：

[1] Sorbonne Univ, Paris, France

[2] Hop St Antoine, Assistance Publ Hop Paris, Paris, France

[3] Vall Hebron Univ Hosp, Barcelona, Spain

[4] Inst Oncol VHIO, Barcelona, Spain

[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Univ Hosp Southern Denmark, Vejle Hosp, Vejle, Denmark

[7] Ctr Hosp Univ Nantes, Nantes, France

[8] Univ Penn, Philadelphia, PA USA

[9] UCM, Hosp Univ 12 Octubre Imas12, Madrid, Spain

[10] Ctr Hosp Univ Poitiers Site Miletrie, Poitiers, France

[11] Hosp Univ Fdn Favaloro, Buenos Aires, Argentina

[12] Centrul Oncol Sf Nectarie, Craiova, Romania

[13] Univ Med & Pharm, Craiova, Romania

[14] Ctr Leon Berard, Lyon, France

[15] Hosp Univ Virgendel Rocio, Seville, Spain

[16] Natl Canc Ctr Hosp East Kashiwa, Chiba, Japan

[17] Shanghai East Hosp, Shanghai, Peoples R China

[18] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[19] Bristol Myers Squibb, Princeton, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.LBA143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA143

引用

页码：LBA143 / LBA143

页数：1

共 50 条

[31] Clinicopathological and genomic characteristics of DNA Mismatch Repair-Deficient (dMMR) and microsatellite instability-high (MSI-H) resected gastric adenocarcinoma
Zhou, J.
Liang, B.
Yin, M.
Zhang, H.
Liu, F.
Dong, L.
Zhang, B.
Xu, Y.
ANNALS OF ONCOLOGY, 2020, 31 : S921 - S922
[32] Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
Overman, Michael J.
Bergamo, Francesca
McDermott, Raymond S.
Aglietta, Massimo
Chen, Franklin
Gelsomino, Fabio
Wong, Mark
Morse, Michael
Van Cutsem, Eric
Hendlisz, Alain
Neyns, Bart
Moss, Rebecca Anne
Zhao, Huanyu
Cao, Z. Alexander
Kamble, Shital
Kopetz, Scott
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[33] Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
Overman, Michael J.
Gelsomino, Fabio
Aglietta, Massimo
Wong, Mark
Limon Miron, Maria Luisa
Leonard, Gregory
Garcia-Alfonso, Pilar
Hill, Andrew G.
Cubillo Gracian, Antonio
Van Cutsem, Eric
El-Rayes, Bassel
McCraith, Stephen M.
He, Beilei
Lei, Ming
Lonardi, Sara
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
[34] Nivolumab plus ipilimumab in microsatellite instability high (MSI)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final survival analysis and prognostic evaluation of GDF-15 in the phase II GERCOR NIPICOL study
Depotte, L.
Nay, P.
Borg, C.
Meurisse, A.
Henriques, J.
Bennouna, J.
de la Fouchardiere, C.
Tougeron, D.
Mazard, T.
Chibaudel, B.
Tournigand, C.
Vernerey, D.
Pigneur, F.
Andre, T.
Cohen, R.
ANNALS OF ONCOLOGY, 2024, 35 : S453 - S454
[35] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year followup from CheckMate 142
Andre, T.
Lonardi, S.
Wong, K.
Lenz, H.
Gelsomino, F.
Aglietta, M.
Morse, M.
Van Cutsem, E.
McDermott, R.
Hill, A.
Sawyer, M.
Hendlisz, A.
Neyns, B.
Abdullaev, S.
Memaj, A.
Lei, M.
Kopetz, S.
Overman, M.
ANNALS OF ONCOLOGY, 2021, 32 : S213 - S214
[36] One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study
Cohen, Romain
Meurisse, Aurelia
Pudlarz, Thomas
Bennouna, Jaafar
Tournigand, Christophe
De La Fouchardiere, Christelle
Tougeron, David
Borg, Christophe
Mazard, Thibault
Chibaudel, Benoist
Garcia-Larnicol, Marie-Line
Svrcek, Magali
Menu, Yves
Vernerey, Dewi
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[37] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
Yoshino, T.
Andre, T.
Kim, T. W.
Yong, W. P.
Shiu, K-K.
Jensen, B. Vittrup
Jensen, L. H.
Punt, C. J. A.
Smith, D.
Garcia-Carbonero, R.
Alcaide-Garcia, J.
Gibbs, P.
de la Fouchardiere, C.
Rivera, F.
Elez Fernandez, M. E.
Le, D. T.
Zuo, Y.
Fogelman, D.
Adelberg, D. E.
Diaz, L.
ANNALS OF ONCOLOGY, 2023, 34 : S1502 - S1503
[38] Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
Overman, Michael J.
Kopetz, Scott
McDermott, Raymond S.
Leach, Joseph
Lonardi, Sara
Lenz, Heinz-Josef
Morse, Michael A.
Desai, Jayesh
Hill, Andrew
Axelson, Michael D.
Moss, Rebecca Anne
Lin, Chen-Sheng
Goldberg, Monica
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[39] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Andre, Thierry
Shiu, Kai-Keen
Kim, Tae Won
Jensen, Benny Vittrup
Jensen, Lars Henrik
Punt, Cornelis J. A.
Smith, Denis Michel
Garcia-Carbonero, Rocio
Alcaide, Julia
Gibbs, Peter
De la Fouchardiere, Christelle
Rivera, Fernando
Elez, Elena
Bendell, Johanna C.
Le, Dung T.
Yoshino, Takayuki
Zhong, Wen Yan
Fogelman, David R.
Marinello, Patricia
Diaz, Luis A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[40] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
Le, D. T.
Diaz, L.
Kim, T. W.
Van Cutsem, E.
Geva, R.
Jager, D.
Hara, H.
Burge, M.
O'Neil, B.
Kavan, P.
Yoshino, T.
Guimbaud, R.
Taniguchi, H.
Elez, E.
Al-Batran, S-E.
Boland, P.
Cui, Y.
Leconte, P.
Marinello, P.
Andre, T.
ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550

← 1 2 3 4 5 →